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Results: Real Time PCR confirmed the increased expression of eSip-L 
in NASH. Western blots demonstrated the expression of eSip-L in liver, 
HepG2 and Huh7 cell lines. Large fluorescent cytoplasmic lipid droplets 
were obtained in all lipid overloaded cells. Immunofluorescence analysis 
showed Sip-L to be localised in the nucleus and cytoplasm. 
Conclusions: eSip-L mRNA expression is upregulated in NASH, high- 
lighting the potential for eSip-L to be utilised as a biomarker for NAFLD. 
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Introduction and Aim: Our previous pilot study showed half the cases 
of drag induced liver injury (DILI) at our unit were due to traditional 
Chinese medicines (TCM), but their toxic components are unknown. This 
prospective study aims to evaluate presence of adulterated medications in
the herbs in TCM-DILI. We achieved this through a collaborative study 
between a clinical hepatology unit and a government pharmacological 
laboratory. 
Methods: All patients admitted to, or referred to our hepatology unit 
for suspected DILI from 1 Sept 2004 to 31 August 2005 were recruited 
and evaluated. Implicated TCMs were sent for further analysis. The test 
protocol categorized 208 commonly encountered drugs in adulterated herbs 
into 37 different pharmacological effect groupings. Depending on the 
volatility of the drugs, the screening protocol used Gas Chromatography/ 
Mass Spectrometry or High performance liquid chromatography/Diode- 
Array Detector to screen for common adulterants. Any positive results 
from HPLC were further confirmed by using Liquid Chromatography/ 
Mass Spectrometry. 
Results: Twenty-four patients with suspected DILI were recruited over 
the 12 months period: median age 53yrs (range 23 79), 12 (50%) male, 
18 (75%) Chinese, 20 (84%) were related to TCM, 1 each related to 
anti-TB drugs, lovastatin, phenytoin, and ketamine. 19 had hepatocellular 
injury, 2 had cholestatic injury, and 3 had mixed injury. Adulterated 
substances were found in 5/24 (21%) preparations of TCM: toxic doses 
of mercury (1), phenylbutazone (1), berberine/codeine (1), berberine/ 
metformin (1), and dexamethasone (1). 1 died from liver failure from 
anti-TB drugs related DILI, 1 who took herbs adulterated with toxic 
doses of mercury developed acute liver failure requiring living donor liver 
transplant, he other 22 (92%) survived. Of note was that 1 inactive hep- 
atitis B carrier who took herbs adulterated with dexamethasone developed 
hepatitis B flare requiring lamivudine therapy; and another male patient 
who took herbs adulterated with phenylbutazone d veloped autoimmune 
hepatitis requiring steroids therapy. 
Conclusion: TCMs could be adulterated with toxins to the liver. Further 
studies on the safety of TCMs including routine testing for adulterated 
substances should be considered. 
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NASH is commonly seen in patients with metabolic syndrome or asso- 
ciated conditions (obesity, diabetes, hyperlipidemia, nd arteriosclerosis). 
White Adipose Tissue (WAT) is a biologically active organ, secreting a
number of factors associated with NASH. 
Aim: To assess the gene expression profiles of patients with NASH in 
both hepatic as well as omental adipose tissue (WAT). 
Methods: Snap-frozen liver biopsy and omental adipose tissue specimens 
were obtained from obese patients with biopsy-proven NASH as well 
as non-NASH controls (lean and obese). From each sample, total RNA 
was extracted, amplified, and reverse transcribed into cDNA probes with 
aminoallyl nucleotides and coupled with fluorescent cyanine 3 or cyanine 5 
dyes. cDNA probes were hybridized with microarray chips containing 
5297 common genes. For each patient, extensive clinico-demographic and 
laboratory data were available. Comparisons were performed using non- 
parametric Mann Whitney tests. Genes deemed statistically significant 
(adjusted p-value <0.05) were extracted for further study. 
Results: Hepatic gene expression was available for 27 NASH patients. 
Adipose tissue gene expression was available for 10 NASH patients. Addi- 
tionally, expression data from 39 controls were available for comparison. In
patients with NASH, fatty-acid-Coenzyme A ligase, long-chain 4 (FACL4) 
was over-expressed in both hepatic and adipose tissues, with a ratio of 
2.5 and 2.2, respectively (p < 0.05). FACL4 is potentially involved in both 
lipid metabolism as well as apoptosis. In assessing genes related to obesity, 
11 genes were differentially expressed in both the omental adipose tissue 
and hepatic tissue of the obese patients. Genes up-regulated in obese 
patients included iodide transporter, sialyltransferase, ulfotransferase, and 
several genes involved in cell contacts. Concordant up-regulation of en- 
dothelin converting enzyme 1 (ECE-1) was also observed in obese patients 
in both tissues, providing a potential link between metabolic syndrome, 
arteriosclerosis, and NASH. 
Conclusions: This study of gene expression in the omental adipose and 
hepatic tissue of patients with NASH shows up-regulation of a number 
of interesting enes associated with lipid metabolism and apoptosis. 
Additionally, up-regulation of ECE-1 may provide a link between NASH 
and arteriosclerosis. 
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Background: Liver involvement is relative common in patients with sickle 
cell disease (SCD) and acute vaso-occlusive crisis, but predisposing factors 
and prevalence are largely unknown. 
Objective: To study prevalence and predisposing factors of liver involve- 
ment in SCD patients in acute vaso-occlusive crisis. 
Design: Prospective study of all SCD cases admitted in acute vaso- 
occlusive crisis during 36 months. 
Setting: Medical Department of a University Hospital. 
Patients: 41 consecutive patients: 44% males; 71% heterozygous (HbSA), 
29% homozygous (HbSS) with median age 33 (17 58) and 42 (16 56) 
years, respectively. 
Measurements: Severity of vaso-occlusive crisis was graded by in-house- 
modified APACHE score; presence of asplenia or functional hyposplenism 
also considered. Hematological and biochemical parameters including 
various relevant enzymes/isoenzymes followed daily. 
Results: Nine (22%) patients presented with acute painful hepatomegaly 
(8 were HbSA). Overall, liver involvement was found in 16 (39%) patients; 
1 had "hepatocellular", 8 "cholestatic" and 7 "mixed" type of liver 
injury. The severity of vaso-occlusive crisis (score 20.6 vs 18.2) was not 
related to liver involvement, but the presence of normal spleen function 
(P < 0.001) and platelet counts <500,000/mm 3 (P < 0.001) were. Patients 
with liver involvement, compared to those without, had higher total and 
